the Challenge

Dr. Bruce Patterson

FOUNDER AND
CHIEF EXECUTIVE OFFICER

Bruce K. Patterson, M.D. is a leading researcher on the effects of viral pathogens on the human immune system. His pioneering technologies and findings have contributed to advances in detection, prognosis and treatment of patients infected with HIV, HPV, cervical cancer, COVID-19 and other diseases.

As Founder and Chief Executive Officer of HealthBioAI, Dr. Patterson developed a new paradigm for predicting, identifying and treating long COVID-19 and other viral pathogens that impair the immune system’s ability to function effectively, as well as a patented treatment protocol for long Covid, currently within the application process with the FDA.

Dr. Patterson received his undergraduate degree in microbiology from the University of Michigan and his M.D. from Northwestern University, where he later served as Chief Resident of Pathology at Northwestern Memorial Hospital. He has authored more than 150 manuscripts and book chapters.

Brian Brothen

CHIEF COMMERCIAL OFFICER

Throughout his career, Brian Brothen has a proven track record of strategic, result-driven, innovative business development in the pharmaceutical, diagnostic and biotech industries. He possesses a keen business acumen and excellent communication, leadership, and problem-solving skills within the C-suite environment.

Brian leverages his 20+ years of successful experience in executive commercial leadership positions.  His track record includes launching and leading biotech sales and business development teams, establishing national physician advisory boards, exceeding financial goals while building strong relationships with key stakeholders. 

Dan Casey

SR. VICE PRESIDENT,
STRATEGIC DEVELOPMENT

Dan brings over 25 years of success in building, launching, and leading commercial teams across companies of all sizes and  specialties including industry leaders Sanofi, Emergent BioSolutions, and Galderma Laboratories.

Demonstrated expertise in strategic and operational planning, Dan excels in shaping innovative customer and patient engagement models, executing national product launches, and adeptly navigating organizational change. The ability to effectively communicate with diverse audiences has been instrumental in aligning various stakeholders to drive success across initiatives within each of his former companies.

What distinguishes Dan is his passion for making a significant impact in the healthcare industry. His commitment to business growth that benefits patients has been a hallmark of his career. Dan prioritizes patient care while achieving and surpassing financial objectives, demonstrating a rare balance of empathy and business acumen.

Throughout his career, Dan has built and led the execution of multiple commercial product launches and co-promotions, generating sales exceeding $2 billion. 

Stefan Glück, MD, PhD

SR. VICE PRESIDENT, MEDICAL AFFAIRS

Stefan Glück, M.D., PhD, is a medical oncologist specializing in breast, ovarian, and bladder cancers, as well as immunology and hematology. He has led early-stage development studies of solid tumors and immuno-oncology. He has deep expertise in clinical trials, acting as the PI in several dozen. 

Dr. Glück has authored/co-authored more than 250 articles, presented more than 350 papers at national and international meetings, and written/co-written multiple book chapters. He is a reviewer of several journals, including the Journal of Clinical Oncology, European Journal of Cancer, Lancet Oncology, Lancet, Breast Cancer Research, The Oncologist, The Breast Journal, and Clinical Breast Cancer.

Dr. Glück was presented the America’s Top Oncologists 2008 award from Consumers’ Research Council of America; he also received the Best Doctors in America honor in since 2006, and has annually earned that prestige every year, including in 2014; this award was warranted after less than 3 years of working in the United States.